Views
4 years ago

47 - F Vidal - Octubre 2007

  • Text
  • Vidal
  • Sustitutivas
  • Vereniclina
  • Acupuntura
  • Tabaco
  • Parches
  • Dejar
  • Bupropion
  • Abstinencia
  • Tratamientos
  • Efectos
  • Dosis
  • Ensayos
  • Tratamiento
  • Nicotina
Actualización del tratamiento de la adicción a nicotina

Psicofarmacología

Psicofarmacología 7:47, Noviembre 2007 los tratamientos implementados deriva del entrenamiento que posea el equipo terapéutico, de la calidad del diagnóstico de la dependencia, de los recursos psicológicos personales y de la adherencia al tratamiento del paciente. Referencias Bibliográficas 1. Riemsma RP, Pattenden J, Bridle C, Sowden AJ, Mather L, Watt IS, et al. Systematic review of the effectiveness of stage based interventions to promote smoking cessation. BMJ 2003;326 (7400):1175-7. 2. Martín F, Corral LP. Tratamiento farmacológico del tabaquismo. Trastornos Adictivos 2004;6(2):103-12. 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4 ed American Psychiatric Association; 1994. 4. West R. Time for change: putting the transtheoretical (stages of change)model to rest. Addiction 2005;100(8):1036-9. 5. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000;55(12):987-99. 6. Regalado-Pineda J, Lara-Rivas G, Osio-Echánove J, Ramírez-Venegas A. Tratamiento actual del tabaquismo. Salud Pública Mex 2007;49(supl 2):S270-S279. 7. US Department of Health and Human Services. Reducing Tobacco Use: A Report of the Surgeon General. Centers for Disease Control and Prevention (CDC), Office on Smoking and Health. 2000. Disponible en: www.cdc.gov/tobacco/sgr/sgr_2000/index.htm. 8. Ronckers S, Ament A. Cost-effectiveness of treatments for tobacco dependence. A systematic Review of the evidence. Human Nutrition Population (HNP) World Bank; 2003. 9. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2002;(4):CD000146. 10. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al. Individualizing Replacement Therapy for the Treatment of Tobacco Dependence: A Randomized Trial. Ann Intern Med 2004;140 (6):426-33. 11. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A, et al. Randomized Comparative Trial of Nicotine Polacrilex, a Transdermal Patch, Nasal Spray, and an Inhaler. Arch Intern Med 1999;159(17):2033-8. 12. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent Advances in the Pharmacotherapy of Smoking. JAMA 1999;281 (1):72-6. 13. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 1999;318(7179):285-8. 14. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, et al. The Clinical Effectiveness and cost-effectiveness of bupropion and nicotine replacements therapy for smoking cessation. a systematic review and economic evaluation. Health Technology Assessment 2002;6(16):1-6. 15. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR. A controlled trial of sustainedrelease bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340(9):685-91. 16. Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, doubleblind, placebo-controlled trial. Arch Intern Med 2000;160(20):3128-34. 17. Ranney L, Melvin C, Lux L, McClain E, Lohr KN. Systematic Review: Smoking Cessation Intervention Strategies for Adults and Adults in Special Populations. Ann Intern Med 2006;145 (11):845-56. 18. Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG. Safety and Effectiveness of Transdermal Nicotine Patch in Smokers Admitted With Acute Coronary Syndromes. Am J Cardiol 2005;95(8):976–8. 19. Hubbard R, Lewis S, Smith C, Godfrey C, Smeeth L, Farrington P, et al. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob. Control 2005;14(6);416-21. 20. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med 2001;135(6):423-33. 21. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337 (17):1195-202. 22. Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation. Arch Intern Med 2004;164(16):1797-803. 23. Zellewer J, Laszio P, Carrozzi L. Bupropin SR vs Placebo for smoking Cessation in Healyh Care Professionals. Am J Health Behav 2005;29(3):240-9. 24. Ministerio de Salud y Ambiente de la Nación, República Argentina. Resumen de la Guía Nacional de tratamiento de la adicción al tabaco: segunda parte. Evidencia Actualización en la Práctica Ambulatoria 2006;9(4):116-20. 25. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist varenicline, for smoking cessation. Arch Intern Med 2006;166 (15):1571-7. 26. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacol 2007;52 (3):985-94. 27. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an α4β2 Nicotinic Acetylcholine Receptor partial agonist, vs sustained release Bupropion and Placebo for Smoking cessation. A randomized controlled trial. JAMA 2006;296(1):47-54. 28. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of Varenicline, an α4β2 Nicotinic acetylcholine receptor partial agonist, vs Placebo os sustained-release Bupropion for smoking cessation. A Randomized Controlled Trail. JAMA 2006;296(1):56-63. 29. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, et al. Effect of maintenance therapy with Varenicline on Smoking Cessation. JAMA 2006;296(1):64-71. 30. Williams KE, Reeves K, Billing CB, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of Varenicline for smoking cessation. Curr Med Res Op 2007;23(4):793-801. 31. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective a4b2 nicotinic receptor partial agonist. Arch Intern Med 2006;166(15):1561-8. 32. Cahill K, Stead JF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007; (1):CD006103. 33. Tutka P, Zatoñski W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep 2005,58 (6):777-99. 34. Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, et al. Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol 2003;64 (6):1283–94. 35. Etter JF. Cytisine for Smoking Cessation: A Literature Review and a Meta-analysis Arch Intern Med 2006;166(15):1553-9. 36. Pabreza LA, Dhawan S, Kellar KJ. [3H]cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol 1991;39(1):9-12. 37. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004; (4):CD000031. 38. Hughes JR, Stead LF, Lancaster T. Antidepresivos para el abandono del hábito de fumar. De La Biblioteca Cochrane Plus, número 3, 2007. Oxford, Update Software Ltd. La Biblioteca Cochrane Plus (ISSN 1745- 9990). 39. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004;(3):CD000058. 40. Hughes JR. Clonidine, depression, and smoking cessation. JAMA 1988;259(19):2901-2. 41. Ornish SA, Zisook S, McAdams LA. Effects of transdermal clonidine treatment on symptoms associated with smoking cessation: a randomized, controlled trial. Arch Intern Med 1988;148(9):2027-31. 42. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. 2000. 43. Stead LF, Hughes JR. Lobelina para dejar de fumar. De La Biblioteca Cochrane Plus, número 2, 2007. Oxford, Update Software Ltd. La Biblioteca Cochrane Plus (ISSN 1745-9990). 44. Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev. 2000; (2):CD000124. 45. Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev. 2000; (2):CD001009. 46. David S, Lancaster T, Stead LF, Evins AE. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003086. 47. David S, Lancaster T, Stead LF, Evins AE. Antagonistas de los opioides para el abandono del hábito de fumar. De La Biblioteca Cochrane Plus, número 3, 2007. Oxford, Update Software Ltd. 48. Sofuoglu M, Babb D, Hatsukami DK. Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers. Nicotine & Tobacco Research 2003;5(6):947-53. 49. Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's bioavailability and decreases smoking. Clin Pharmacol Ther 2000;68(1):35-43. 50. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev 2007;(4):CD005353. 51. Lancaster T, Stead LF. Silver acetate for smoking cessation. Cochrane Database Syst Rev. 2000; (2):CD000191. 52. Lancaster T and Stead LF. Acetato de plata para dejar de fumar (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Oxford: Update Software. 53. White AR, Rampes H and Ernst E. Acupuncture for smoking cessation. (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Oxford: Update Software. Bier ID,Wilson J, Studt P, Shakleton M.. Auricular acupuncture, education, and smoking cessation: a randomized, sham-controlled trial. Am J Public Health 2002; 92(10):1642-7. 54. White AR, Resch KL, Ernst E. A meta-analysis of acupuncture techniques for smoking cessation. Tob Control 1999;8(4):393-7. 55. White AR, Rampes H, Campbell JL. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD000009. 56. Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD002849. DOI: 10.1002/1465185 8.CD002849. 57. Hughes JR, Stead LF and Lancaster T. Anxiolytics for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Oxford: Update Software. EDITORIAL SCIENS // 37

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015